Australia's most trusted
source of pharma news
Wednesday, 05 February 2025
Posted 23 August 2024 AM
After Roche officially abandoned Gavreto, its former partner Blueprint Medicines (BPM) has failed to find a new commercialisation partnership in Australia.
Gavreto was provisionally registered in March 2023 for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC), beating Eli Lilly's Retevmo in becoming the first RET inhibitor to be approved by the TGA.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.